{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"457","upperLimit":"637","value":"497"},{"comment":"Insufficient number of participants with events; therefore, upper limit of 95% CI not reached.","groupId":"OG001","lowerLimit":"449","upperLimit":"NA","value":"583"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"43"}],"units":"Participants"}],"description":"DOR was defined as length from the earliest date a participant achieved a complete response (CR) or partial response (PR) to either date for disease progression (including relapse from CR) or the censoring date for progressive disease. Responders without disease progression were censored at the last efficacy assessment for disease progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"Velcade 1.3 mg/m2 was administered as an intravenous bolus injection according to the current approved package inserts. Melphalan 9 mg/m2 and prednisone 60 mg/m2 were taken orally.","id":"OG000","title":"Part 2: VMP (Velcade+Melphalan+Prednisone)"},{"description":"Siltuximab 11 mg/kg as a 1-hour intravenous infusion every 3 weeks along with VMP. VMP: Velcade 1.3 mg/m2 was administered as an intravenous bolus injection according to the current approved package inserts. Melphalan 9 mg/m2 and prednisone 60 mg/m2 were taken orally.","id":"OG001","title":"Part 2: VMP (Velcade+Melphalan+Prednisone) + Siltuximab"}],"paramType":"MEDIAN","populationDescription":"Included participants in the randomized population who achieved CR or PR.","reportingStatus":"POSTED","timeFrame":"From the date participants achieved CR or PR to either date for disease progression (including relapse from CR) or the censoring date for progressive disease, as assessed Up to 30 days after last dose of study medication","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"Days"}